Learn why the next frontier in AI governance will involve real-time surveillance of algorithmic performance across institutions with guidance from Akshaya Bhagavathula and Michelle A. Williams.
- Virtual Reality Endpoints Improve Measurement Of Patients' Real-World Benefit
- Can't-Miss Advice On Selecting Your First AI-Enabled Vendor
- The Site Perspective: Why Ambient AI Is The Missing Link In Clinical Trial Data Integrity
- Why HEOR Keeps Arriving Too Late — And How ClinOps Can Fix It
- Accelerating Clinical Innovation With Open-Source Medical Platforms
- From Supercomputers To The Cloud: How Pharma's R&D Infrastructure Transformation Impacts Clinical Trials
- How To Identify Patient-Centric Risks In The TMF With AI And Automation
- How The TMF Demonstrates Patient Safety And Rights In DCTs
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Discover Why Electronic Revisions Of ICFs Are Easier
What does the ICF amendment or revision process look like within a digital platform and is this harder or easier than traditional paper-based approaches?
-
Why The Everest Group Named Medable A Leader In eCOA
Discover how this eCOA is leading the charge in accelerating study timelines, boosting patient engagement, and answering real sponsor needs.
-
Providing Drug Supply Support In Complex Environments Through IRT
Learn how applying predictive data analytics can enable the creation of an ideal supply strategy capable of reducing the need for extra shipments, manual oversight, and supply waste.
-
Webinar Recap: How EDC Can Support Modern Clinical Trials
Gain insights from our recent webinar focused on the critical role EDC systems play in supporting modern working practices and innovative trial designs, structured around four key themes.
-
How DCTs Became The New Standard
See how the core features of DCTs have become the new default clinical trial practices for a variety of therapeutic areas, almost four years after the 2020 pandemic brought about their rise.
-
Broadening Eligibility Criteria Among Cancer Clinical Trials Patients
This study challenges the commonly applied exclusionary approach to clinical trials, particularly cancer trials, that underrepresent certain populations and limit the generalizability of research advancements.
-
Analyzing The FDA's Approach To Diversity In Clinical Trials
Learn how utilizing diverse data resources and collaborating with stakeholders enables sponsors to foster a culture of inclusivity, meet regulatory requirements and ultimately advance medical science.
-
Letter From The CEO: A New Era Of Drug Development Is Here
This letter from Medable CEO Michelle Longmire lays out why we created Studio, what it enables sponsors and CROs to do, and how it will help everyone bring more effective therapies to patients faster.
-
4 Key eCOA Benefits To Speed Up Your Clinical Trial
As the healthcare landscape moves towards a patient-centric approach, explore how sponsors and regulatory bodies look to eCOAs more and more for obtaining patient data.
-
What Happened At ASCO 2024
Discover our associates' insights on the key developments from ASCO 2024 that are set to shape the future of cancer care and patient outcomes.